Clinical Research Directory

Inclusion Criteria: * Patients with Multiple Sclerosis (any clinical form) or Neuromyelitis optica spectrum disease seropositive for aquaporin-4 antibodies (AQP4+) * Aged 18 years or more * Treated with anti-CD20 mAbs (Rituximab IV or Ocrelizumab IV or SC) since \< 2 years with dosing intervals of 6 months (and for Rituximab, treated with 1g per infusion) * Planned to receive the same anti-CD20 mAbs with dosing intervals of 6 months during the 13 months of the study (and for Rituximab, planned to receive 1g per infusion) * Known history in the medical file of varicella, or VZV IgG serology known to evidence a prior infection * Affiliated or beneficiary of a social security scheme * Written and informed consent * Understands and agrees to comply with the study procedures Exclusion Criteria: * Temporary contraindication to vaccination (concurrent episode of acute fever \>38.5°C) * Shingles in the last 12 months or VZV vaccination in the last 5 years * Patients already treated or supposed to be treated with Ofatumumab (another anti-CD20 mAbs but delivered with a monthly subcutaneous injection) * Patients who received high dose corticosteroids (methylprednisolone at a dose of ≥ 500 mg, administered over 1 to 5 days) in the 3 months prior to inclusion * Patients who have been exposed to Cladribine in the prior 12 months * Patients who received or were scheduled to receive any vaccination, except for influenza and SARS-CoV-2 vaccines during the epidemic season, within 2 weeks prior to the 2 RZV injections and up to 4 weeks after the second RZV injection * Hypersensitivity to the active substance or to one of the excipients * Patient protected by the law (guardianship, curatorship) * Pregnancy or breast-feeding * Women of childbearing potential (WOCBP) without effective contraception throughout the duration of the trial * Criteria related to the use of ancillary anti-CD20 treatments (Rituximab and Ocrelizumab): Hypersensitivity to the active substance or to any of the excipients Severe, active infections Severe immunodeficiency Severe heart failure or severe uncontrolled heart disease Known progressive malignancies